At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
In Brief
A Phase 2 clinical trial evaluating Conventional Surgery, Laboratory Biomarker Analysis, and 2 other interventions for Adult Glioblastoma and 2 related conditions. Completed, enrolled 115 participants across 190 sites.
Detailed Summary
This phase I/II trial studies the side effects and best dose of temsirolimus when given together with sorafenib tosylate and to see how well they work in treating patients with glioblastoma that has come back. Sorafenib tosylate may stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as temsirolimus, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib tosylate and temsirolimus may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving sorafenib tosylate with temsirolimus may kill more tumor cells.
Study Details
Timeline
Interventions
Undergo surgery
Correlative studies
Given PO
Given IV